Streetbeat News

Products Services

META

Meta Platforms, Inc. has introduced video calling features to its Ray-Ban smart glasses, enabling users to make calls through WhatsApp and Messenger. This update signifies Meta's ongoing efforts to integrate its social media services more deeply with wearable technology, potentially increasing user engagement across its platforms.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 3:50 pm

LLY

Market whales have shown a bullish stance on Eli Lilly and Co (NYSE:LLY), with 55% of detected trades being bullish and 20% bearish. The trading activity focuses on a price range between $600.0 and $1160.0. Notable options activity includes both puts and calls with varying sentiments and strike prices. Eli Lilly, a drug firm specializing in several therapeutic areas, has seen its stock price increase by 1.41%, with a current price of $741.64. The next earnings report is expected in 7 days.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 3:45 pm

META

Meta is integrating video calling features between WhatsApp and Messenger, allowing users to share their views during a video call, as reported by Reuters.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 3:43 pm

DOGEUSD

PEPEUSD

SHIBUSD

Cryptocurrency trader Vapor predicts that at least three meme coins will surpass a $100 billion market cap, highlighting their advantages over other crypto investments. Meme coins are seen as simpler, more sustainable, more liquid, and safer than other options. The Benzinga Twitter poll showed GME Coin, Shiba Inu (SHIB), Dogecoin (DOGE), and Pepe (PEPE) as top meme coins according to readers' votes. This prediction underscores the growing influence and potential of meme coins in the cryptocurrency market.

Portfolio Pulse from Khyathi Dalal

April 23, 2024 | 3:39 pm

CDNS

GM

SMH

The Arora Report indicates profitable hedges and semiconductor stabilization after a 17% drop, highlighting the sector's leading role and its central position in the AI revolution. Notable earnings from General Motors and Cadence Design Systems show mixed signals for the market. Early trade money flows are positive for several tech giants, neutral for Apple, and mixed for major ETFs. The article also discusses strategies for protection bands and portfolio adjustments in the current market environment.

Portfolio Pulse from The Arora Report

April 23, 2024 | 3:25 pm

BTCUSD

Morgan Creek Capital CEO Mark Yusko challenges Bitcoin skeptic Peter Schiff to a $1M charity bet on Bitcoin vs. gold performance over the next 5 years. Yusko supports Bitcoin, while Schiff, a gold bull, has not yet responded. The challenge highlights the ongoing debate between Bitcoin and traditional investment assets like gold, with Yusko having a price target of $150,000 for Bitcoin in the next year.

Portfolio Pulse from Chris Katje

April 23, 2024 | 3:03 pm

AAPL

Apple Inc. (NASDAQ:AAPL) has scheduled a special event for May 7 to unveil new iPad models, including expected upgrades to the iPad Pro such as an OLED display, an updated M3 chipset, and a repositioned front-facing camera. The event, themed 'Let loose,' may also introduce a new Apple Pencil and a redesigned Magic Keyboard. This announcement comes as Apple aims to rejuvenate its iPad and Mac sales amidst a reported 19% drop in iPhone sales in China during the March 2024 quarter.

Portfolio Pulse from Rounak Jain

April 23, 2024 | 2:58 pm

PRME

Prime Medicine's stock is trading higher following the announcement of upcoming presentations of preclinical data for its Prime Editing technology, indicating progress in its programs.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 2:54 pm

AAPL

Apple has announced a 'Let Loose' event scheduled for May 7, 2024, which is anticipated to introduce new products or updates. This announcement is likely to generate significant interest among investors and consumers, potentially impacting Apple's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 2:41 pm

BGNE

BeiGene's stock is trading higher following the European Commission's approval of Tislelizumab for non-small cell lung cancer, covering first- and second-line use across three indications.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 2:40 pm